WATERTOWN, Mass., Jan. 12, 2026 — Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) for in vivo gene delivery, announced Dyno-yp2, a novel adeno-associated virus (AAV) gene delivery vector engineered for central nervous system (CNS) applications. Dyno-yp2 demonstrates efficient and selective CNS delivery by binding the human transferrin receptor (hTfR1) to cross the blood-brain barrier (BBB) in TfR-humanized mice.
In preclinical studies, Dyno-yp2 achieved over 94% neuronal transduction, an 11-fold improvement in brain biodistribution compared to BI-hTFR1, and significant liver detargeting—80-fold versus BI-hTFR1 and 29-fold versus AAV9. These results highlight Dyno-yp2’s combination of potent CNS AAV transduction and reduced off-target exposure.
Dyno-yp2 was designed using Dyno’s AI-driven platform, which integrates billions of in vivo measurements to optimize AAV capsids for high-potential BBB-crossing mechanisms. The vector is available for licensing and evaluation through Dyno’s Frontiers Program, supporting rapid in vivo testing of therapeutic payloads.
Dyno continues to advance AAV capsids across multiple CNS delivery mechanisms, including TfR1 and alkaline phosphatase (ALPL), demonstrating strategic delivery agility for gene therapy developers. Dyno-yp2 complements Dyno’s existing AAV capsid portfolio, including Dyno-bn8 (muscle), Dyno-3hv (neuromuscular), Dyno-4z2 (ocular), and Dyno-ahq (CNS), reflecting the company’s approach to overcoming persistent AAV gene therapy delivery challenges.
Source:
https://www.businesswire.com/news/home/20260112827255/en/Dyno-Therapeutics-Launches-Dyno-yp2-a-Top-Performing-TfR1-Mediated-AAV-Capsid-to-Further-Diversify-CNS-Delivery-Portfolio
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related Services
-
Custom mRNA Service
- High-quality mRNA with full QC panel
- Custom scales, stability, and modifications
- End-to-end support from design to manufacturing
-
Custom mRNA-LNP Service
- Increased stability with protected mRNA delivery
- Enhanced uptake via optimized LNP formulations
- Reduced immunogenicity for safer applications
-
Fast mRNA Service for Gene Editing
- Cas9, Nickase, Cre, and more for gene editing
- Fast, on-demand delivery for urgent projects
- N1-methyl-pseudo Uridine to reduce immune response
